^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BCR-ABL1 mutation

    i
    Other names: BCR, BCR Activator Of RhoGEF And GTPase, BCR, RhoGEF And GTPase Activating Protein, Breakpoint Cluster Region Protein, Renal Carcinoma Antigen NY-REN-26, Breakpoint Cluster Region, D22S11, BCR1, BCR/FGFR1 Chimera Protein, FGFR1/BCR Chimera Protein, D22S662, ALL, CML, PHL, ABL proto-oncogene 1, ABL, c-ABL, JTK7, p150, ABL1
    Entrez ID:
    25; 613
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over1year
    Olverembatinib Benefit Holds Up in BCR-ABL1 T315I-Mutant, TKI-Resistant CML @ASH_hematology #mpnsm #ASH22 https://t.co/d4GwbtyWaV (@OncLive)
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation
    |
    Nailike (olverembatinib)
    2years
    CML patients with high risk mutations do well with #BMT - disease control more important than presence of mutations The clinical significance of BCR-ABL1 mutations in patients with Ph+ chronic myeloid leukemia who underwent allo HCT @ASTCT_Journal #leusm https://t.co/maJgRSz9jg (@BldCancerDoc)
    Clinical
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    BCR-ABL1 mutation
    over2years
    Paper No: 307 #ASH21 Post Hoc Analysis of Responses to Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia By Baseline BCR-ABL1 Level and Baseline Mutation Status in the Optic Trial #CML @espGELMC (@jvalentingg)
    Clinical • Retrospective data
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    BCR-ABL1 mutation
    |
    Iclusig (ponatinib)